# Intravitreal Aflibercept for the Prevention of Proliferative Vitreoretinopathy Following Retinal Detachment Repair

> **NCT04580147** · PHASE2 · UNKNOWN · sponsor: **M. Ali Khan, MD** · enrollment: 150 (estimated)

## Conditions studied

- Retinal Detachment With Multiple Breaks, Unspecified Eye
- Proliferative Vitreoretinopathy

## Interventions

- **DRUG:** Intravitreal aflibercept injection
- **OTHER:** Sham control

## Key facts

- **NCT ID:** NCT04580147
- **Lead sponsor:** M. Ali Khan, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-15
- **Primary completion:** 2023-09-15
- **Final completion:** 2023-12-15
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2022-05-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04580147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04580147, "Intravitreal Aflibercept for the Prevention of Proliferative Vitreoretinopathy Following Retinal Detachment Repair". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04580147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*